Cabinet of Ministers Regulations No. 509 of 2007 in Riga on July 24 (pr. No 42 24) amendments to the Cabinet of Ministers of 30 November 2004, the Regulation No 974 "Doping Control rules" Issued in accordance with article 6 of the law of sports in the fifth subparagraph of paragraph 4, the draw of the Cabinet of Ministers of 30 November 2004, the Regulation No 974 "Doping Control rules" (Latvian journal, 2004, no. 192; 2006, nr. 49) the following amendments: 1. Express 38 as follows: "38. the Agency's officer sends the sample cover letter and a copy of the questionnaire of the doping control to the doping control laboratory who is accredited to the Council of Europe Anti-Doping Convention monitoring group criteria laid down and that is accredited by the World Anti-Doping Agency in accordance with the International Convention against doping in sport (laboratory). The covering letter noted the sport or discipline in which athletes in participate, sampling date and time collected urine sample volume, pH and specific gravity of the urine sample kit number or the blood sample Kit code, as well as the information provided by the athlete for the last 10 days of medication used. " 2. Make annex 1 as follows: "annex 1 Cabinet 30 November 2004 the Regulation No 974 Doping substances and doping methods no Doping substances or methods p.k. Group Subgroup Doping substance or method notes 1. S1. Anabolic means S 1.1. Androgenic-anabolic steroids S 1.1 (a). Exogenous anabolic steroids are androgenic 1-androstendiol (5-andros-1-en-3.17-diol); 1-androstendion (5-andros-1-3.17-Dione-en); bolandiol (19-norandrostenediol); bolasteron; boldenon; boldion (androst-1.4-3.17-Dione-days); calusteron; clostebol; danazol (17-ethynyl-17-hydroxyandros-4-en-[2,3-d] isoxazol); dehydrochlormethyltestosteron (4-hydroxy-chlor-17-17-methylandrost-1.4-day-3-one); desoxymethyltestosteron (17-methyl-5-andros-2-en-17-ol); drostanolon; ethylestrenol (19-nor-17-pregn-4-en-17-ol); fluoxymesteron; formebolon; furazabol (17-hydroxy-androstan-17-methyl-5-[2,3-c] furazan-); gestrinon; 4-hydroxytestosteron (4.17-dihydroxyandros-4-en-3-one); mestanolon; mesterolon; metenolon; methandienon (17-hydroxy-17-methylandrost-1.4-day-3-one); methandriol; methasteron (2, 17-dimethyl-5-androstan-3-one-17-ol); methyldienolon (17-hydroxy-17-methylestr-4.9-day-3-one); methyl-1-testosterone (17-hydroxy-17-methyl-5-andros-1-en-3-one); methylnortestosteron (17-hydroxy-17-methylestr-4-en-3-one); methyltrienolon (17-hydroxy-17-methylestr-4, 9-3, 11-trien-one); methyltestosteron; miboleron; nandrolone; 19-norandrostenedion (estr-4-en-3.17-Dione); norboleton; norclostebol; norethandrolon; oxabolon; oxandrolon; oxymesteron; oxymetholon; prostanozol ([3,2-c] pyrazol-5-17-tetrahydropyranol etioallocholan-); quinbolon; stanozolol; stenbolon; 1-testosterone (17-hydroxy-5-andros-1-en-3-one); tetrahydrogestrinon (18-Homo-pregn-4, 9, 11-17-ol-trien-3-one); trenbolone and other substances with a similar chemical structure or similar biological effect of Exogenous-that body cannot develop natural Endogenous b-S 1.1.-Anabolic Androgenic Steroids Androstenediol (andros-5-en-3.17-diol); androstenedion (andros-4-en-3.17-Dione); dihydrotestosteron (17-hydroxy-androstan-3-one-5); prasteron (dehydroepiandrosteron, DHEA); Testosterone metabolites and isomers such as: 5-androstan-3.17-1,2-diol; 5-androstan-3.17-1,2-diol; 5-androstan-3.17-1,2-diol; 5-androstan-3.17-1,2-diol; andros-4-en-3.17-1,2-diol; andros-4-en-3.17-1,2-diol; andros-4-en-3.17-1,2-diol; andros-5-3.17-diol; en- andros-5-3.17-diol; en- andros-5-3.17-diol; en- 4-androstenediol (andros-4-en-3.17-diol); 5-androstenedion (andros-5-3.17-Dione-en); EPI-dihydrotestosteron; 3-hydroxy-androstan-17-5-one; 3-hydroxy-androstan-17-5-one; 19-norandrosterone; 19-norethiocholanolone Endogenous-substance that the body can develop naturally on the doping substance being considered in the sample where androgenic anabolic steroid in the body may develop naturally and that doping substances or its metabolites, or diagnostic markers or other indicators of concentration in the sample differ from what the concentration normally found in the human body and is associated with the development of the endogenous. If an athlete proves that a doping substance or for its metabolites or markers or other indicators of concentration in the sample is a physiological phenomenon or pathological consequences, believe that doping substances in the sample is found. If, on the basis of reliable analytical methods (e.g. IRMs), the laboratory results may demonstrate that doping substances are exogenous in origin, the presence of substances in doping sample believes all deposits in any concentration and the laboratory report on the doping substance found in the sample. In this case, you do not need additional study. If a laboratory reports that the concentration does not differ from that of the concentration normally found in the human body, and the reliable analytical method (e.g. IRMs), the results do not indicate the origin of the exogenous substance, but there are serious indications, such as steroid profile comparison, about possible doping substances, additional studies, the evaluation of any previous test results or making further tests to determine the outcome of such physiological or pathological cause or exogenous origin of the substance use of doping. If a laboratory reports that testosterone (T) and (E) the ratio epitestosteron athlete's urine is greater than four to one (4:1), and any use of reliable analytical method (e.g. IRMs), the results do not indicate the origin of the exogenous substance, you can make additional investigations, evaluation of the results of previous checks, or making further checks to determine whether the result is a physiological or pathological state, or it had to be of exogenous origin of doping substances. If a laboratory reports that used reliable analytical method (e.g. IRMs), the results indicate the exogenous origin of the substance, further investigations are required and believes that the sample contains doping substances. If additional reliable analytical method (e.g. IRMs) has not been used and is not available for a minimum of three previous test results, carried out at least three athletes for unannounced inspections in three months. If the athlete profile longitudin placing these checks do not conform to the norms of physiological Announces adverse analytical fields. Especially in rare cases of endogenous origin boldenon can be regularly found in the urine in very small concentrations (nanograms per millilitre, (ng/ml)). If the laboratory reports in such low concentrations boldenon and any used reliable analytical methods (for example, IRMs) results do not indicate the exogenous origin of the substance, further investigation can be performed when assessing the results of previous checks or performing further checks. If additional reliable analytical method (e.g. IRMs) has not been used and is not available for a minimum of three previous test results, carried out at least three athletes for unannounced inspections in three months. If the athlete profile longitudināl these checks do not meet the physiological norm, announces adverse analytical fields. If a laboratory reports an adverse analytical norandrostenon the lookup in the 19-event, such recognition is considered to be scientific and reasonable evidence of doping substances for exogenous origin. In such cases, do not require additional study. If the athlete refuses to participate in studies, believes that the sample contains doping substance S 1.2. Other features Clenbuterol anabolic, zeranol, zilpaterol tibolon, and other anabolic features 2. S2. Hormones and similar substances 1. Erythropoietin (EPO). 2. Growth hormone (hGH), insulin-like growth factor (IGF-1 for example), motor growth factor (MGF). 3. the Gonadotrophin (LH; hCG), prohibited in males only. 4. the insulin. 5. Kortikotropīn. 6. Other substances with a similar chemical structure or similar biological effect and it atbrīvotājfaktor if a doping substance or its metabolites or markers of diagnostic concentration or other indicator differs from the sample concentration, one normally finds in the human body and which is not associated with endogenous development, this substance and the athlete can prove that this concentration is a physiological phenomenon or pathological effects, it is considered that the sample found doping substances. If the laboratory using a reliable analytical method, finds that a doping substance is of exogenous origin, assumes that the sample contains doping substances, and shall report on the laboratory adverse analytical fields. If the sample of certain other substances with a similar chemical structure or biological effects or diagnostic markers of those hormones, or atbrīvotājfaktor, or other data that indicate that the substance is found naturally developed hormone laboratory report adverse analytical fields 3. S3. But all but a-2 agonists-2 agonists, including their D-and L-isomers is an exception, formoterol, salbutamol and salmeterol inhalation terbutalīn use that requires the use of a therapeutic authorisation (in abbreviated form) If a laboratory report on salbutamol (free and glikuronizēt) koncen trācij the urine over 1000 ng/ml (nanograms per millilitre) athlete, who served a therapeutic authorisation, it is regarded as doping substances being samples, unless the athlete can demonstrate that such deposits are the consequences of the use of salbutamol inhalation treatment purposes 4. S4. Features with anti-estrogenic activity


1. Aromatase inhibitors including, anastrozol letrozol, aminoglutethimid, formestan, testolacton, exemestan and other features. 2. Selective estrogen receptor modulator (SERM), including tamoxifen, toremifen raloxifen, and other features. 3. other anti-estrogenic compounds, including fulvestran, cyclofenil, clomiphen and other compounds 5. S5. Diuretic and masking features diuretic probenecid, līdzekļi1), Epitestosteron alpha-reductase inhibitors (e.g. finasteride, dutasterid), a plasma substitute (such as albumin, dekstrān, hidroksietilciet), and other līdzekļi2) 1), amilorid Acetazolamid, bumetanid, canrenon, chlorthalidon, etakrīnskāb, furosemid, indapamid, metolazon, spironolacton, thiazide (e.g. bendroflumethiazid, chlorothiazid, hydrochlorothiazid), triamteren and other substances with a similar chemical structure or similar biological effect (except drosperidon which is not prohibited). 2) therapeutic use permit shall cease to be valid if an athlete's urine contains a diuretic product with other doping substances, which is the highest allowed concentration limits or slightly below 6. M. Doping methods M1. Oxygen transport function improvement 1. Blood doping, including the origin of any of autologous, homologous or heterolog blood or red blood cells entering the product. 2. the acquisition of oxygen, improvement of transport or delivery, including the chemical, perfluor efaproxiral (RSR13), modified haemoglobin products (e.g. haemoglobin in blood substitutes on the base, mikroinkapsulēt, haemoglobin products) and other methods use M2. Chemical and physical manipulation 1. Doping control samples collected during the deterioration of or damage to attempt to change the validity and integrity of the sample. Such action shall be deemed katetrizācij, urine substitution and/or alteration, as well as other manipulations. 2. Intravenous infusion, except medical treatment for acute cases M3. Gene doping is not justified in Therapeutic cell, gene, genetic elements, or of the modulation of gene expression, which can improve the sportisko achievements 7. S6. Stimulatori1 Adrafinil, adrenaline2), amfepramon), amiphenazol, benzphetamin, amphetaminil amphetamin,, benzylpiperazin,, cathine3), bromantan, clobenzorex cocain, cropropamid, crotetamid, cyclazodon, dimethylamphetamin, ephedrine4), etilamphetamin, etamivan, etilefrin, famprofazon, fenbutrazat, fencamin, fenetyllin, fencamfamin, fenproporex, furfenorex, fenfluramin, heptaminol, isomethepten, levmethamfetamin, meclofenoxat, mefenorex, mephentermin, mesocarb, methamphetamin (D-), methylenedioxyamphetamin, methylenedioxymethamphetamin, p-methylamphetamin, methylephedrine4), methylphenidat, modafinil, nikethamid, norfenefrin, norfenfluramin, octopamin, ortetamin, oxilofrin, parahydroxyamphetamin, pemolin, phenmetrazin pentetrazol, phendimetrazine, phentermine, phenpromethamin, 4-phenylpiracet (carphedon) prolintan, propylhexedrin, selegilin, sibutramine, strychnin, tuaminoheptan and other substances with a similar chemical structure or similar biological substances have) 1), included in the 2007 monitoring program (bupropion, caffein, ylpropanolamin, phen phenylephrin, pipradol, pseudoephedrine, synephrin), are not considered doping substances. 2) adrenaline with a local anesthetic, or local use (e.g., nose, eyes) is not prohibited. 3) is forbidden to use the Cathin if its concentration in urine greater than 5 micrograms per millilitre. 4) and methylephedrin use of Ephedrin is prohibited, if their concentration in urine is greater than 10 micrograms per millilitre. 5) Stimulator, which is mentioned as an example in this chapter, be considered as a particular substance only if the athlete can prove that this substance can lead to unintentional anti-doping rule violation, as it is widely available in the medical product, or it's not considered doping to be used successfully to feature 8. S7. Drugs Buprenorphin, dextromoramid, diamorphin (heroin), fentanyl and its derivatives, hydromorphon, methadon, morphin, oxycodon, oxymorphon, pentazocin, pethidin 9. S8. Kanabinoīd in Kanabinoīd (e.g. hashish, marijuana) 10. S9. Glucocorticosteroid glucocorticosteroid, if all things oral, rectal, intramuscular or intravenous injection of. This requires the use of a therapeutic exemption permit all other input types (intraartikul, periartikulār, peritendinoz race, epidurāl and intra dermal injection, as well as inhalation) requires the use of a therapeutic authorisation (in abbreviated form). Domestic use containing a glucocorticosteroid medication are not prohibited and do not require the use of a therapeutic authorisation when used Dermatologic, ear, nose, eyes, and mucous membranes of the mouth and gums, perianāl diseases, including jonoforēz and fonoforēz in the note. The specific substances are: 1) all beta-2 agonists, except salbutamol-(free and glikuronizēt), if its concentration in urine is greater than 1000ng/ml and clenbuterol; 2) Probenecid; 3), cropropamid, crotetamid cathin, ephedrin, etamivan, famprofazon, heptaminol, isomethepten, levmethamfetamin, meclofenoxat, p-methylamphetamin, methylephedrin, nikethamid, norfenefrin, octopamin, ortetamin, oxilofrin, phenpromethamin, propylhexedrin, tuaminoheptan, selegilin, sibutramine and any other stimulant not mentioned in chapter but S6 athlete proves that it meets the requirements set out in section S6; 4) kanabinoīd; 5) any glucocorticosteroid; 6) alcohol; 7) all beta blockers. "
Prime Minister a. Halloween Health Minister v. Veldr MC